Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Accepts Priority Review for Dostarlimab in dMMR/MSI-H Rectal Cancer

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

The US FDA has granted priority review to dostarlimab for the treatment of dMMR/MSI-H rectal cancer, accelerating its potential approval timeline.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 24 Aug 2026 and 25 Aug 2026.

◆ ◆ The Wire takeaway

Biotech founders focused on immuno-oncology now face faster US approval pathways for checkpoint inhibitors in colorectal cancer. You should accelerate clinical and regulatory engagement to capitalise on clearer FDA priority pathways.

◆ Coverage

4 sources · first reported 24 Aug 2026 · latest 25 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdapriority-reviewrectal-cancerimmunotherapydostarlimab